Ameliorative effects of resveratrol on liver injury in streptozotocin-induced diabetic rats.
The objective of this study was to investigate the ameliorative property and potential mechanism of resveratrol (RVT) in a dose of 10 mg/kg for 15 consecutive days against liver injury in streptozotocin-induced diabetic rats. Diabetic rats significantly (P < 0.05) exhibited liver injury manifested by increased aspartylaminotransferase, alanine aminotransferase, and bilirubin; disturbed liver weight to body weight; and confirmed by hematoxylin and eosin staining. Liver from diabetic rats exhibited significant increase in malondialdehyde level and significant decrease in reduced glutathione, glutathione-S-transferase, quinone reductase, catalase, and superoxide dismutase. Diabetic rats showed significant disturbance in serum lipid profile. Treatment with RVT significantly (P < 0.05) abrogated diabetes-induced perturbation in these parameters and liver histology. These data suggest that RVT treatment is associated with promising hepatoprotective effect against diabetes-induced liver damage via reduction of serum glucose level and oxidative damage and improving serum lipid profile.
Department of Biology, Mentouri Mahmoud University, Constantine, Algeria.
Nasereddine
N
Hamadi
Ahmed
A
Mansour
Memy H
MH
Hassan
Fatima
F
Khalifi-Touhami
Osama
O
Badary
D000818:Animals; D000893:Anti-Inflammatory Agents / Q000494:pharmacology / Q000627:therapeutic use*; D000975:Antioxidants / Q000494:pharmacology / Q000627:therapeutic use*; D001786:Blood Glucose; D003921:Diabetes Mellitus, Experimental / Q000097:blood / Q000150:complications / Q000188:drug therapy*; D015227:Lipid Peroxidation; D008055:Lipids / Q000097:blood; D008099:Liver / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D008107:Liver Diseases / Q000097:blood / Q000188:drug therapy* / Q000209:etiology; D008297:Male; D008315:Malondialdehyde / Q000378:metabolism; D009929:Organ Size / Q000187:drug effects; D018384:Oxidative Stress; D051381:Rats; D017207:Rats, Sprague-Dawley; D000077185:Resveratrol; D013267:Stilbenes / Q000494:pharmacology / Q000627:therapeutic use*; D013311:Streptozocin
D000893:Anti-Inflammatory Agents; D000975:Antioxidants; D001786:Blood Glucose; D008055:Lipids; D013267:Stilbenes; D008315:Malondialdehyde; D013311:Streptozocin; D000077185:Resveratrol